5. GENERALIDADES DE DISTRIBUCIONES ROCAS LTDA
5.3. VISION ACTUAL DE DISTRIBUCIONES ROCAS LTDA.
53BP1 TP53-binding protein 1
AKT1 RAC-alpha serine/threonine-protein kinase ALT Alternative Lengthening of Telomeres AML Acute Myeloid Leukaemia
Arf Tumor suppressor ARF
ARID1A AT-rich interactive domain-containing protein 1A ATM Ataxia telangiectasia mutated
ATMi ATM inhibitor
ATP Adenosine Triphosphate
ATR Ataxia telangiectasia and Rad3-related protein ATRi ATR inhibitor
ATRIP ATR Interacting Protein
BRCA1 Breast cancer type 1 susceptibility protein BRCA2 Breast cancer type 2 susceptibility protein CCNE1 Cyclin E1
CD8 T-cell surface glycoprotein CD8
CDC2 CDK1
CDC25A M-phase inducer phosphatase 1 CDC25C M-phase inducer phosphatase 3 CDK1 Cyclin-dependent Kinase 1 CDK2 Cyclin-dependent Kinase 2 CDK4 Cyclin-dependent Kinase 4 CDK9 Cyclin-dependent Kinase 9 CHK1 Checkpoint kinase-1 CHK1i CHK1 inhibitor CHK2 Checkpoint kinase-2 CHK2i CHK2 inhibitor
CLL Chronic Lymphocytic leukaemia
CRISPR Clustered regularly interspaced short palindromic repeats CSR Class Switch Recombination
CTIP CtBP-interacting protein
CTLA-4 Cytotoxic T-lymphocyte protein 4 DDR DNA Damage Response
DNA Deoxyribonucleic Acid
DNA-PK DNA-dependent Protein Kinase
DNA-PKcs DNA-dependent Protein Kinase catalytic subunit DNA-PKi DNA-PK inhibitor
dNTP Deoxyribonucleotide triphosphate DSB Double Strand Break
dsDNA Double stranded DNA
EGFR Epidermal growth factor receptor
ERCC1 Excision Repair Cross-Complementation Group 1 ERCC4 Excision Repair Cross-Complementation Group 4 EZH2 Enhancer of zeste homolog 2
FANC Fanconi anemia
FANCC Fanconi anemia group C protein FANCG Fanconi anemia group G protein H2AX Histone H2A.X
HDAC Histone Deacetylase
HR Homologous Recombination
HRD Homologous Recombination Deficiency IGFR1 Insulin-like growth factor I
IR Ionising Radiation
KDM6A Lysine-specific demethylase 6A KRAS Kirsten rat sarcoma viral oncogene MCL Mantle Cell Lymphoma
MDM2 Double minute 2 protein
MHC Major histocompatibility complex MK2 MAP kinase-activated protein kinase 2 MLH1 MutL protein homolog 1
MMC Mitomycin C MMR Mismatch repair MSH3 MutS Homolog 3
mTOR Mechanistic target of rapamycin NHEJ Non-homologous end joining NKG2D Natural Killer Group 2, member D NKT Natural Killer T-cell
NSCLC Non-Small Cell Lung Cancer PARP Poly ADP ribose polymerase PARPi PARP inhibitor
PD1 Programmed cell death protein 1 PDL1 Programmed death-ligand 1
PIKK Phosphatidyl inositol 3’ kinase-related kinases
PKMYT1 Protein Kinase, membrane associated tyrosine/threonine 1 PLK1 Polo-Like Kinase 1
POLD1 Polymerase D1
RAD1 RAD1 checkpoint DNA exonuclease
RAD17 RAD17 checkpoint Clamp Loader component RAD9A RAD9 checkpoint Clamp component A
RAD51C DNA repair protein RAD51 homolog 3 RAD51D DNA repair protein RAD51 homolog 4
REV3L REV3 like, DNA directed polymerase zeta catalytic subunit REV7 MAD2L2: Mitotic Arrest Deficient 2 like 2
RNA Ribonucleic Acid
RRM2 Ribonucleoside-diphosphate reductase subunit M2 SETD2 SET domain-containing protein 2
SMO Smoothened homolog ssDNA Single Stranded DNA TLS Trans Lesion Synthesis TOP2A Topoisomerase IIA
TOPBP1 DNA topoisomerase 2-binding protein 1 UV Ultraviolet (light)
VHL Von Hippel-Lindau disease tumor suppressor WEE1 WEE1 G2 checkpoint kinase
WEE1i WEE1 inhibitor
XPF Xeroderma Pigmentosum, complementation group F γH2AX H2AX phosphorylated at S139
References
= of interest, = of considerable interest
[1] Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411:366–374.
[2] Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481:287–294.
[3] Rundle S, Bradbury A, Drew Y, et al. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017;9:41.
[4] Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer. 2017;17:93–115.
[5] Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 2013;14:197–210.
[6] Bhattacharya S, Srinivasan K, Abdisalaam S, et al. RAD51
interconnects between DNA replication, DNA repair and immunity. Nucleic Acids Res. 2017;45:4590–4605.
[7] Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
[8] Kersten K, de Visser KE, van Miltenburg MH, et al. Genetically
engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 2016;9:137–153.
[9] Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011. p. 646–674.
[10] McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017;168:613–628.
[11] Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071–1078.
[12] Karakaidos P, Zacharatos P, Kotsinas A, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;907–913.
Describes the activation of the DDR in response to oncogene activation [13] Bartkova J, Rezaei N, Liontos M, et al. Oncogene-induced senescence
is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–637.
Describes the activation of the DDR in response to oncogene activation [14] Toledo LI, Murga M, Zur R, et al. A cell-based screen identifies ATR
inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 2011;18:721–727.
Describes the identification of ATR inhibitors and synthtic lethal interactions with Cyclin E1 overexpression and/or p53 loss
[15] Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat. Cell Biol. 2014;16:2–9.
[16] Drean A, Lord CJ, Ashworth A. PARP inhibitor combination therapy. Crit. Rev. Oncol. 2016;108:73–85.
[17] Lord CJ, Ashworth A. PARP inhibitors: Synthetic Lethality in the clinic. Science (80-. ). 2017;355:1152–1158.
[18] Lavin, M.F., Khanna, K.K., Beamish, H., Spring, K., Watters, D., Shiloh Y. Relationship of the ataxia-telangiectasia protein ATM to
phosphoinositide 3- kinase. Trends Biochem. Sci. 1995;20:382–383. [19] Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA
damage response signaling network. Clin. Cancer Res. 2010;16:376– 383.
[20] Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J. Mol. Cell Biol. 2014;6:442–457.
[21] Tresini M, Warmerdam DO, Kolovos P, et al. The core spliceosome as target and effector of non-canonical ATM signalling. Nature.
2015;523:53–58.
[22] Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic
mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:18250–18255.
[23] Hickson I, Zhao Y, Richardson CJ, et al. Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-
Telangiectasia Mutated Kinase ATM Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM. Cancer Res. 2004;64:9152–9159.
[24] Golding SE, Rosenberg E, Valerie N, et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009;8:2894–2902.
[25] Weber AM, Ryan AJ. ATM and ATR as therapeutic targets in cancer. Pharmacol. Ther. 2015. p. 124–138.
[26] Batey MA, Zhao Y, Kyle S, et al. Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and
dysfunctional models of human cancer. Mol. Cancer Ther. 2013;12:959–967.
[27] Pike KG. Identifying high quality, potent and selective inhibtors of ATM kinase: Discovery of AZD0156. Proceeding 107th Annu. Meet. if Am. Assoc. Cancer Res. 2016.
[28] Nakayama Y, Igarashi A, Kikuchi I, et al. Bleomycin-induced over- replication involves sustained inhibition of mitotic entry through the ATM/ATR pathway. Exp. Cell Res. 2009;315:2515–2528.
[29] Hsiang YH, Lihou MG, Liu LF. Arrest of Replication Forks by Drug- stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin. Cancer Res. 1989;49:5077–5082. [30] Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end
resection. Nature. 2007;450:509–514.
[31] Bakr A, Oing C, Köcher S, et al. Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015;43:3154–3166.
[32] Williamson C, Muzik H, Turhan A. ATM deficiency sensitizes mantle cell lymphoma cells to poly (ADP-ribose) polymerase-1 inhibitors. Mol. Cancer Ther. 2010;9:347–357.
[33] McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP- ribose) polymerase inhibition. Cancer Res. 2006;66:8109–8115. [34] Biddlestone-Thorpe L, Sajjad M, Rosenberg E, et al. ATM kinase
inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin. Cancer Res. 2013;19:3189–3200.
[35] Williamson CT, Kubota E, Hamill JD, et al. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol. Med. 2012;4:515–527.
[36] Menezes DL, Holt J, Tang Y, et al. A Synthetic Lethal Screen Reveals Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell
Lymphoma with ATM Loss-of-function. Mol Cancer Res. 2014;13:pii: molcanres.0240.2014.
[37] Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat. Chem. Biol. 2011;7:428–430.
Describes the synergy between small molecule ATR inhibitors and platinum salts in pre-clinical models of p53 mutant cancer
[38] Cui Y, Palii SS, Innes CL, et al. Depletion of atr selectively sensitizes atmdeficient human mammary epithelial cells to ionizing radiation and dna-damaging agents. Cell Cycle. 2014;13:3541–3550.
[39] Bunting SF, Callén E, Wong N, et al. 53BP1 inhibits homologous recombination in brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141:243–254.
[40] Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double- strand break resection and affects PARP inhibition. Nature.
2015;521:541–544.
[41] Shen JP, Zhao D, Sasik R, et al. Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions. Nat. Methods. 2017;14.
CRISPR-Cas9 genetic screen that exploits a "dual-guide RNA" approach which identifies synthetic lethal interactions involving DDR and tumour suppressor genes.
[42] Lecona E, Fernández-Capetillo O. Replication stress and cancer: It takes two to tango. Exp. Cell Res. 2014. p. 26–34.
[43] Yazinski SA, Zou L. Functions, Regulation, and Therapeutic Implications of the ATR Checkpoint Pathway. Annu. Rev. Genet. 2015;1–19.
[44] Lee J, Kumagai a, Dunphy WG. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol. Biol. Cell. 2001;12:551–563.
[45] Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-Cyclin B Complex by the Human WEE1 Tyrosine Kinase. Science (80-. ). 1992;257:1955–1957.
[46] Charrier JD, Durrant SJ, Golec JMC, et al. Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents. J. Med. Chem. 2011;54:2320–2330.
[47] Fokas E, Prevo R, Pollard JR, et al. Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis. 2012;3:e441.
[48] Foote KM, Blades K, Cronin A, et al. Discovery of 4-{4-[(3R)‑3-
Methylmorpholin-4-yl]-6-[1- (methylsulfonyl)cyclopropyl]pyrimidin-2-yl}- 1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity. J Med Chem. 2013;56:2125–2138.
[49] Karnitz LM, Zou L. Molecular pathways: Targeting ATR in cancer therapy. Clin. Cancer Res. 2015;21:4780–4785.
[50] Peasland A, Wang L-Z, Rowling E, et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br. J. Cancer. 2011;105:372–381.
[51] Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and
chemotherapy. Cancer Biol. Ther. 2012;13:1072–1081.
[52] Huntoon CJ, Flatten KS, Wahner Hendrickson AE, et al. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Res. 2013;73:3683–3691.
[53] Jossé R, Martin SE, Guha R, et al. ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014;74:6968–6978.
[54] Biskup E, Naym DG, Gniadecki R. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation. J. Dermatol. Sci. 2016;3.
[55] Sanjiv K, Hagenkort A, Calderón-Montaño JM, et al. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 2016;14:298–309.
[56] Mohni KN, Thompson PS, Luzwick JW, et al. A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments. PLoS One. 2015;10.
[57] Huang KK, Jang KW, Kim S, et al. Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck. Sci. Rep. 2016;6:19552.
[58] Mohni KN, Kavanaugh GM, Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ercc1 deficiency. Cancer Res. 2014;74:2835–2845.
[59] Kwok M, Davies N, Agathanggelou A, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells. Blood. 2016;127:582–595. [60] Menezes DL, Holt J, Tang Y, et al. A Synthetic Lethal Screen Reveals
Enhanced Sensitivity to ATR Inhibitor Treatment in Mantle Cell Lymphoma with ATM Loss-of-function. Mol Cancer Res. 2014;
[61] Hocke S, Guo Y, Job A, et al. A synthetic lethal screen identifies ATR- inhibition as a novel therapeutic approach for POLD1-deficient cancers. Oncotarget. 2016;7:7080–7095.
[62] Williamson CT, Miller R, Pemberton HN, et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat. Commun. 2016;7:13837.
[63] Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and
bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 2013;45:592–601. [64] Nieto-Soler M, Morgado-Palacin I, Lafarga V, et al. Efficacy of ATR
inhibitors as single agents in Ewing sarcoma. Oncotarget. 2016;7:58759–58767.
[65] Jones S, Fleuren E, Frankum J. ATR is a therapeutic target in synovial sarcoma. Cancer Res. (in press).
[66] Flynn RL, Cox KE, Jeitany M, et al. Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science (80-. ).
2015;347:273–277.
[67] Deeg KI, Chung I, Bauer C, et al. Cancer cells with alternative lengthening of telomeres do not display a general hypersensitivity to ATR inhibition. Front. Oncol. 2016;6:0–13.
[68] Brown JS, OCarrigan B, Jackson SP, et al. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov. 2016;20–38.
[69] Colicchia V, Petroni M, Guarguaglini G, et al. PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma. Oncogene. 2017;1–10.
[70] Mouw KW, Goldberg MS, Konstantinopoulos PA, et al. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017;617–632.
[71] Ruiz S, Mayor-Ruiz C, Lafarga V, et al. A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors. Mol. Cell. 2016;62:307–313.
[72] Jette N, Lees-Miller SP. The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis. Prog. Biophys. Mol. Biol. 2015;117:194–205.
[73] van der Burg M, van Dongen JJM, van Gent DC. DNA-PKcs deficiency in human: long predicted, finally found. Curr. Opin. Allergy Clin.
Immunol. 2009;9:503–509.
[74] Beskow C, Skikuniene J, Holgersson a, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br. J. Cancer. 2009;101:816–821.
[75] Bouchaert P, Guerif S, Debiais C, et al. DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2012;84:1179–1185.
[76] Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood. 2005;106:3175–3182. [77] Zhou Z, Patel M, Ng N, et al. Identification of synthetic lethality of
PRKDC in MYC-dependent human cancers by pooled shRNA screening. BMC Cancer. 2014;14:944.
[78] Riabinska A, Daheim M, Herter-Sprie GS, et al. Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors. Sci. Transl. Med. 2013;5:189ra78.
[79] Dietlein F, Thelen L, Jokic M, et al. A functional cancer genomics
screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discov. 2014;4:592–605.
[80] Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat. Rev. Cancer. 2016;16:234–249. [81] Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining
drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc. Natl. Acad. Sci. U. S. A. 2011;108:3406–3411.
[82] Gatei M, Sloper K, Sörensen C, et al. Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J. Biol. Chem. 2003;278:14806–14811. [83] Busino L, Donzelli M, Chiesa M, et al. Degradation of Cdc25A by beta-
2003;426:87–91.
[84] Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 1997;277:1497–1501.
[85] Calvo E, Chen V, Marshall M, et al. Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs. 2014;32:955–968.
[86] Karp JE, Thomas BM, Greer JM, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin. Cancer Res. 2012;18:6723– 6731.
[87] Chen Z, Xiao Z, Gu WZ, et al. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer. 2006;119:2784–2794.
[88] Bridges KA, Chen X, Liu H, et al. MK-8776, a novel chk1 kinase
inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget. 2016;15.
[89] Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int. J. Cancer. 2014;134:1013–1023.
[90] Scagliotti G, Kang J, Smith D, et al. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Invest New Drugs. 2016;34:625–635.
Phase II clinical trial data for the CHK1 inhibitor LY2603618 [91] Rawlinson R, Massey AJ. γH2AX and Chk1 phosphorylation as
predictive pharmacodynamic biomarkers of Chk1 inhibitor-
chemotherapy combination treatments. BMC Cancer. 2014;14:483. [92] Bryant C, Rawlinson R, Massey AJ. Chk1 Inhibition as a novel
therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014;14.
[93] Xiao Z, Xue J, Gu W-Z, et al. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors. Biomarkers. 2008;13:579–596.
[94] Sakurikar N, Thompson R, Montano R, et al. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase. Oncotarget. 2016;7:1380–1394. [95] Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of
S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle. 2007;6:104–110.
[96] Chaudhuri L, Vincelette ND, Koh BD, et al. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica. 2014;99:688–696.
[97] Magnussen GI, Emilsen E, Giller Fleten K, et al. Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer. 2015;15:462.
[98] Dietlein F, Kalb B, Jokic M, et al. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell. 2015;162:146– 159.
combination therapy
[99] Ahn JY, Li X, Davis HL, et al. Phosphorylation of threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the forkhead-associated domain. J. Biol. Chem. 2002;277:19389– 19395.
[100] Bartek J, Falck J, Lukas J. CHK2 kinase--a busy messenger. Nat. Rev. Mol. Cell Biol. 2001;2:877–886.
[101] Jobson AG, Lountos GT, Lorenzi PL, et al. Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2- carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J. Pharmacol. Exp. Ther. 2009;331:816–826.
[102] Caldwell JJ, Welsh EJ, Matijssen C, et al. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J. Med. Chem. 2011;54:580–590.
[103] Anderson VE, Walton MI, Eve PD, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011;71:463–472.
[104] Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel